|
FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
|
06 March 2015 |
|
Novartis announces completion of transactions with GSK
|
02 March 2015 |
|
Novartis receives FDA approval of Farydak®, the first HDAC inhibitor for patients with multiple myeloma
|
24 February 2015 |
|
Novartis Pharmaceuticals announces a joint investment company with Qualcomm
|
13 January 2015 |
|
Novartis collaborates with Intellia Therapeutics and Caribou Biosciences
|
07 January 2015 |
|
Novartis Foundation symposium showcases sustainable healthcare interventions
|
21 November 2014 |
|
New data on the global economic impact and burden of preventable blindness and vision impairment
|
09 October 2014 |
|
Novartis announces clinical collaboration to evaluate Bristol-Myers Squibb's novel immunotherapy in combination treatments for NSCLC
|
06 October 2014 |
|
Novartis' new heart failure medicine LCZ696 cut cardiovascular deaths by 20% vs. ACE-inhibitor in landmark PARADIGM-HF trial
|
02 September 2014 |
|
Novartis provides drug candidate compounds to TB Alliance
|
20 August 2014 |